News

A new precision drug targeting cancer’s ability to repair its DNA has shown promising results in a clinical trial. The study, designed to test the drug’s safety, found that half of the participants given the new drug either alone or with platinum chemotherapy saw their cancer stop growing, and two participants saw their tumors shrink or disappear completely.

A major Phase 3 trial of capivasertib, a cancer drug has begun. The trial will enrol ~830 patients across 20 countries and will examine the effects of the drug in premenopausal or postmenopausal women, and men, with an advanced form of oestrogen receptor-positive, human epidermal growth factor receptor 2 negative breast cancer.

An innovative use of focused ultrasound is showing promise against glioblastoma and could prove useful against other difficult-to-treat cancers.

Scientists seeking to understand the mechanism of a DNA-repairing protein have discovered that the molecule performs its functions by first marking and then further breaking damaged DNA.

New research, conducted by a team from the University of California San Diego School of Medicine, indicates that the manipulation of macrophages, could be a viable treatment strategy for cancer.

A new program named PATRIOT, is using organoids to provide a whole new level of accuracy in prescribing anti-cancer treatments to patients.

A simple but highly sensitive blood test has been shown to accurately diagnose and classify different types of brain tumor.

Scientists have developed a novel liquid biopsy method that can detect kidney cancers with high accuracy, including small, localized tumors which are often curable but for which no early detection method exists.

Jan Korbel and Oliver Stegle, both group leaders at EMBL Heidelberg, have performed a survey of fellow life scientists in Germany, Spain, the UK, Italy, France, Canada, Turkey, and the USA to learn how the current crisis, with partial or complete institutional shutdowns, is affecting their work.

Researchers at Children's Cancer Institute have discovered what could prove a new and improved way to treat the poor-prognosis blood cancer, acute myeloid leukaemia or AML.